Economic evaluation of prostate cancer screening with prostate‐specific antigen
Authors:
- 1 April 2008
- journal article
- review article
- Published by Wiley in International Journal of Urology
- Vol. 15 (4) , 285-288
Abstract
Economic issues cannot be ignored in conducting prostate cancer screening using prostate-specific antigen (PSA). Through an electronic search, we reviewed five descriptive cost studies and nine cost-effectiveness/cost-utility analyses concerning PSA screening. Most of the existing evidence was based on mathematical model analysis and the results are enormously disparate. The cost per quality-adjusted life years (QALY) gained was estimated to be $US 63.37 to $68.32, and $8400 to $23 100, respectively, or was dominated by no screening. Economic studies evaluating PSA screening are still far from sufficient. Urologists, epidemiologists and health economists must jointly conduct further studies on not only mortality but also quality of life assessment and economic evaluation, using randomized clinical trials, for a strict evaluation of the actual efficacy of PSA screening. At present, patients should be thoroughly informed of the limitations of PSA screening and, in consultation with urological specialists, make the personal decision of whether to receive it.Keywords
This publication has 25 references indexed in Scilit:
- Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effectiveEuropean Journal of Surgical Oncology, 2007
- Prostate CancerJournal of Urology, 2007
- Screening for prostate cancer2006
- Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screeningUrology, 2002
- Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancerThe Prostate, 2000
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996
- Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection programUrology, 1995
- Screening for prostate cancer. A decision analytic view1994
- An evaluation of prostate-specific antigen as a screening test for prostate cancerArchives of internal medicine (1960), 1993
- Prostate Cancer Screening: What We Know and What We Need To KnowAnnals of Internal Medicine, 1993